Evogene (EVGN) Beginning Cash Balance (2011 - 2026)

Evogene has disclosed Beginning Cash Balance across 16 years of filings, most recently posting $13.0 million for Q2 2026.

• In Q2 2026, Beginning Cash Balance fell 15.33% year-over-year to $13.0 million; the TTM figure through Jun 2026 stood at $13.0 million (down 15.33% YoY), while the FY2025 annual figure was $15.3 million, down 26.34% from the prior year.
• Beginning Cash Balance came in at $13.0 million for Q2 2026 at Evogene, down from $15.3 million in the prior quarter.
• In the past five years, Beginning Cash Balance ranged from a high of $32.3 million in Q2 2022 to a low of $13.0 million in Q2 2026.
• Average Beginning Cash Balance over 5 years is $23.5 million, with a median of $20.8 million recorded in 2024.
• Year-over-year, Beginning Cash Balance tumbled 30.08% in 2022 and slipped 10.35% in 2023.
• Over 5 years, Beginning Cash Balance stood at $32.3 million in 2022, then dropped by 10.35% to $29.0 million in 2023, then slipped by 28.32% to $20.8 million in 2024, then dropped by 26.34% to $15.3 million in 2025, then slipped by 15.33% to $13.0 million in 2026.
• Per Business Quant data, the three most recent Beginning Cash Balance figures were $13.0 million in Q2 2026, $15.3 million in Q4 2025, and $15.3 million in Q3 2025.